Elanco

United States Companion Animal Health Market Report 2022: Market to Reach $11.39 Bn by 2030 - Rising Number of Companion Ownership - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 1, 2022
Health, Veterinary, Pets, Consumer, Dog, Boehringer Ingelheim Animal Health, Association, Coronavirus, American Pet Products Association, Insurance, Telehealth, COVID-19, Market share, Animal, PETS, Boehringer Ingelheim, Medication, Solution, Therapy, Investment, Vaccine, Growth, Health, Adoption, Big data, Industry, Merck, Pet, Fine chemical, Marketing, Elanco

The rising number of pet owners seeking better healthcare services, healthier quality foods, and high-end grooming and training services for their companion animals is a major driver for this market.

Key Points: 
  • The rising number of pet owners seeking better healthcare services, healthier quality foods, and high-end grooming and training services for their companion animals is a major driver for this market.
  • With the rising adoption of companion animals and growing concerns over their health, there comes a direct association with pet insurance.
  • Approval of novel therapeutics and companion animal vaccines continues to present this market with lucrative growth opportunities.
  • Companies are adopting various strategies to gain competitive advantages, such as new product development, partnerships, mergers and acquisitions, collaborations, and regional expansion.

Elanco to Participate in Stifel 2022 Jaws and Paws Conference

Retrieved on: 
Monday, May 23, 2022
Health, Veterinary, Pets, Consumer, Veterinarian, Disease, Elanco, Health, Farmer, Interpersonal relationship, PETS, Conference, Animal, ELAN, NYSE, CEO, Veterinary medicine, Food

Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Stifel 2022 Jaws and Paws Conference on Wednesday, June 1, 2022.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Stifel 2022 Jaws and Paws Conference on Wednesday, June 1, 2022.
  • Jeff Simmons, president and CEO, will participate in a fireside chat at 3:00 p.m.
  • A live audio webcast will be available in the Events and Presentations section of Elancos investor website .
  • At Elanco, were driven by our vision of Food and Companionship Enriching life and our Elanco Healthy Purpose CSR framework all to advance the health of animals, people and the planet.

Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose

Retrieved on: 
Monday, May 23, 2022
Health, FDA, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Risk, RNA transfection, Company, Immunotherapy, Private Securities Litigation Reform Act, Peer review, U.S. Securities and Exchange Commission, Hoffmann-La Roche, EUA, Science, Infection, Vaccine, Vaccination, Elanco, Clinical trial, BNT162, COVID-19, Marketing, Research, BioNTech, Pediatrics, DO, Facebook, Awareness, YouTube, Regeneron Pharmaceuticals, Program, Safety, LinkedIn, Twitter, Pierre Geneves, SEC, Pfizer–BioNTech COVID-19 vaccine, News, Cancer, Publication, Annual report, Pharmaceutical industry, Pfizer, Genentech

We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

Key Points: 
  • We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • We routinely post information that may be important to investors on our website at www.Pfizer.com .
  • The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.

Digital Additive Celebrates 10 Years of One-to-One Connection

Retrieved on: 
Monday, May 9, 2022
Cloud, Online, Salesforce Marketing Cloud, Communication, Assurant, GLOBE, The Home Depot, Fleetcor, Online marketplace, Family, Industry, Financial services, Marketing, Health, Friends, Final good, Growth, Digital, Public relations, Elanco, Vermiculite, Nordstrom

ATLANTA, May 09, 2022 (GLOBE NEWSWIRE) -- Digital Additive, an award-winning eCRM-focused agency specializing in Salesforce Marketing Cloud, proudly celebrates its 10th anniversary today.

Key Points: 
  • ATLANTA, May 09, 2022 (GLOBE NEWSWIRE) -- Digital Additive, an award-winning eCRM-focused agency specializing in Salesforce Marketing Cloud, proudly celebrates its 10th anniversary today.
  • From starting out in a shared co-working space with three full-time employees to their current, expanded office space in the Zonolite community, Digital Additive continues on an impressive growth trajectory.
  • The Digital Additive team is now over 50 colleagues strong, with employees all over the country and as far afield as Japan and Spain.
  • As the agency has grown, Digital Additive has excelled in numerous verticals including Retail & Consumer Goods, Financial Services, and Online Marketplaces.

Elanco and Royal DSM Announce Strategic Alliance in U.S. for Bovaer® – A Revolutionary, Methane-Reducing Feed Product for Cattle

Retrieved on: 
Wednesday, April 27, 2022
General Health, Consumer, Agriculture, Natural Resources, Other Manufacturing, Environment, Fitness & Nutrition, Science, Veterinary, Health, Pets, Other Science, Manufacturing, Meat, CEO, Veterinarian, Carbon, Climate change, Farmer, U.S. Securities and Exchange Commission, Security (finance), Risk, Dairy, DSM (company), Euronext Amsterdam, ESG, Energy Independence and Security Act of 2007, Tree, Livestock, Securities Exchange Act of 1934, Nutrition, Solution, PETS, Forward-looking statement, Methane, Royal, Animal, NYSE, Global Methane Initiative, Interpersonal relationship, Multimedia, Disease, Securities Act of 1933, ELAN, DSM, Pharmaceutical industry, Renewable energy, Health, Food, Elanco

Elanco has secured the exclusive U.S. licensing rights to develop, manufacture and commercialize Bovaer for beef and dairy cattle.

Key Points: 
  • Elanco has secured the exclusive U.S. licensing rights to develop, manufacture and commercialize Bovaer for beef and dairy cattle.
  • View the full release here: https://www.businesswire.com/news/home/20220426006220/en/
    Elanco and Royal DSM Announce Strategic Alliance in U.S. for Bovaer A Revolutionary, Methane-Reducing Feed Additive for Cattle (Photo: Business Wire)
    Bovaer is a first-in-class methane-reducing product for beef and dairy cattle approved in Europe, Brazil, Chile and Australia.
  • This alliance will help us realize Bovaers potential as a powerful solution with a significantly positive impact on the planet.
  • In addition, and fully aligned with our purpose-led performance-driven strategy, the alliance enables us as DSM to monetize our long-term innovation faster.

Elanco and Royal DSM Announce Strategic Alliance in U.S. for Bovaer® - A Revolutionary, Methane-Reducing Feed Additive for Cattle

Retrieved on: 
Wednesday, April 27, 2022
Meat, CEO, Veterinarian, Food system, Carbon, Climate change, Farmer, Dairy, DSM (company), Euronext Amsterdam, ESG, Livestock, Nutrition, Solution, PETS, Methane, Royal, Animal, NYSE, Global Methane Initiative, Interpersonal relationship, Disease, ELAN, DSM, Agriculture, Pharmaceutical industry, Fine chemical, Renewable energy, Health, Food, Elanco

Elanco has secured the exclusive U.S. licensing rights to develop, manufacture and commercialize Bovaer for beef and dairy cattle.

Key Points: 
  • Elanco has secured the exclusive U.S. licensing rights to develop, manufacture and commercialize Bovaer for beef and dairy cattle.
  • Bovaer is a first-in-class and best-in-class methane-reducing innovative feed additive for beef and dairy cattle, already available in Europe, Brazil, Chile and Australia.
  • In addition, and fully aligned with our purpose-led performance-driven strategy, the alliance enables us as DSM to monetize our long-term innovation faster."
  • Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company.

Elanco Confirms Date and Conference Call for First Quarter 2022 Financial Results Announcement

Retrieved on: 
Thursday, April 14, 2022
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, NYSE, Elanco, Veterinarian, Animal, Disease, Health, ELAN, Farmer, PETS, Interpersonal relationship, Video game, Food

Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2022 financial results on Monday, May 9, 2022.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2022 financial results on Monday, May 9, 2022.
  • Elanco will also conduct a conference call on that day with the investment community and media to further detail the companys performance.
  • The conference call will begin at 8:00 a.m. eastern time.
  • Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elancos website at https://investor.elanco.com/events-and-presentations/default.aspx .

Elanco Breaks Ground on State-of-the-Art Campus, Creating Indianapolis’ Newest Landmark

Retrieved on: 
Tuesday, April 12, 2022
Veterinary, Other Retail, Pets, Health, Consumer, General Health, Retail, Agriculture, Natural Resources, CEO, Veterinarian, White River, Farmer, Securities and Exchange Commission (Philippines), Multi, Security (finance), Research, Creation, Eli Lilly and Company, Private Securities Litigation Reform Act, Form 10-K, Ownership, Growth, Central State Hospital (Indiana), Form, Company, City, Â, PETS, Forward-looking statement, Interpersonal relationship, Animal, NYSE, General Motors, High Alpha Research Vehicle, Circle, Multimedia, Partnership, Disease, Health, ELAN, Grassland, Interior design, Amusement park, Food, White River State Park, Elanco

View the full release here: https://www.businesswire.com/news/home/20220412005510/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220412005510/en/
    Elanco Breaks Ground on State-of-the-Art Campus, Creating Indianapolis Newest Landmark (Photo: Business Wire)
    The company which grew from a small division of Eli Lilly & Company to a $4.7 billion independent global animal health leader plans to enter its seventh decade by breathing life into a long-idle site close to its birthplace.
  • When we talk about the new headquarters, were talking about building as a verb, not a noun, said Jeff Simmons, Elanco president and CEO.
  • Finally, we believe Indianapolis is poised to become an epicenter of animal health innovation, and were excited to be among the architects building its foundation.
  • Robust amenities and services designed to accommodate employee flexibility and evolving, personal workstyles while fueling the Elanco culture of ownership and innovation.

Elanco Animal Health Incorporated Announces Early Results of Tender Offer and Increase in Tender Cap for 2023 Notes

Retrieved on: 
Tuesday, April 12, 2022
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, Veterinarian, Farmer, Debt-to-GDP ratio, U.S. Securities and Exchange Commission, Security (finance), Risk, Sale, Securities Act of 1933, Securities Exchange Act of 1934, Person, Broker, Prospectus, PETS, Forward-looking statement, Interpersonal relationship, Exchange, Animal, NYSE, Note, Disease, Citigroup, Health, ELAN, Online gambling, Food, Elanco

Except with respect to the increase in the Tender Cap, all the conditions set forth in the Offer to Purchase remain unchanged.

Key Points: 
  • Except with respect to the increase in the Tender Cap, all the conditions set forth in the Offer to Purchase remain unchanged.
  • If any of the conditions are not satisfied, Elanco may terminate the Offer and return tendered Notes not previously accepted.
  • Elanco has the right to waive any of the foregoing conditions with respect to the Notes and to consummate the Offer.
  • Holders must make their own decisions as to whether to tender their Notes, and, if so, the principal amount of Notes to tender.

BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines

Retrieved on: 
Monday, April 11, 2022
Company, Private Securities Litigation Reform Act, Form 10-K, Partnership, DNA, Elanco, Sale, Nano, Immunotherapy, Forward-looking statement, Patient, NYSE, Vaccine, Research, SEC, Risk, BioNTech, Cancer, Regeneron Pharmaceuticals, Hoffmann-La Roche, Technology, LNC, Organic acid, RNA transfection, Nasdaq, Geneve 9640, GLOBE, Solution, Consultant, BNTX, Annual report, History, Infection, Fine chemical, Genentech, Pfizer

This can be achieved with the right technology that enables targeted vaccine delivery, said Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech.

Key Points: 
  • This can be achieved with the right technology that enables targeted vaccine delivery, said Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech.
  • Matinas LNC platform demonstrates encouraging capabilities for intracellular delivery, including the opportunity for oral delivery.
  • Under the terms of the agreement, Matinas will receive an upfront access fee to work exclusively with BioNTech, as well as additional research funding from BioNTech.
  • Matinas BioPharma is a biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.